David Ure, CEO of Inanovate

The integration of Sanford’s breast cancer biomarkers with our Bio-ID biomarker analysis platform provides a unique solution to breast cancer detection and monitoring. This technology could enable the detection of recurrent breast cancer at a stage when it may be more effectively treated and cured.